Insider Trading History of Dorling Janet

The following table details the insider trading activities (stock purchases, stock sales, and stock option exercises) of Dorling Janet since 2018. This trader's CIK number is 1738144. At the time of last reporting, Dorling Janet was the Director of Cymabay Therapeutics, Inc.. (stock ticker symbol CBAY). Also see all insider trading activities at Cymabay Therapeutics, Inc..

Note that in the past Dorling Janet also reported insider trading activities as an insider of the following companies:

Yearly summary of insider trading at Cymabay Therapeutics, Inc. (CBAY) by Dorling Janet

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2024 CBAY 0 $0 12,000 $334,992 12,000 $55,560
2023 CBAY 0 $0 6,000 $120,420 6,000 $27,780

Yearly summary of insider trading at Achaogen, Inc. (AKAO) by Dorling Janet

Insider Buying Insider Sales Option Exercises
Year Symbol Shares Value Shares Value Shares Value
2019 AKAO 0 $0 1,881 $2,050 0 $0
2018 AKAO 0 $0 450 $4,315 0 $0


Insider trading activities at 2 companies by Dorling Janet:

1. Cymabay Therapeutics, Inc. (CBAY)

2. Achaogen, Inc. (AKAO)

Table 1. Insider trading of Cymabay Therapeutics, Inc. (CBAY) by Dorling Janet

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2024-02-12 CBAY Option Ex 6,000 4.63 27,780
2024-02-12 CBAY Sale 6,000 31.98 191,850
2024-01-10 CBAY Sale 6,000 23.86 143,142
2024-01-10 CBAY Option Ex 6,000 4.63 27,780
2023-12-11 CBAY Sale 6,000 20.07 120,420
2023-12-11 CBAY Option Ex 6,000 4.63 27,780

Table 2. Insider trading of Achaogen, Inc. (AKAO) by Dorling Janet

Trade Date Symbol Trade Type Shares Price ($) Value ($)
2019-02-21 AKAO Sale 1,063 .89 946
2019-02-05 AKAO Sale 818 1.35 1,104
2018-06-26 AKAO Sale 450 9.59 4,315

Insider trading activities including stock purchases, stock sales, and option exercises listed in the above table cannot be completely guaranteed as to their accuracy. For more information regarding the trades made by Dorling Janet (Director of Cymabay Therapeutics, Inc. at the time of this reporting) see the Securities and Exchange Commission (SEC) website.



©2023, insider-monitor.com. All rights reserved.